摘要
白细胞介素-35(interleukin,IL-35)是近年来新发现的由调节性T细胞(regulatory T cell,Treg)产生的抑制性细胞因子,其中IL-35是由IL-27β链Epstein-Barr病毒诱导体3(Epstein-Barr virus-induced gene 3,EBI3)和IL-12α链p35组成的异二聚体。近几年研究发现,T细胞、B细胞和肿瘤细胞等均可分泌IL-35,其对机体免疫系统产生抑制效应。IL-35在肿瘤免疫逃逸、促进肿瘤进展及转移过程中发挥作用,是促进肿瘤发生发展的重要因素,减少IL-35分泌可能有助于控制疾病进展。了解IL-35在调节肿瘤细胞生命活动中的作用较为重要。本文对IL-35的分子结构、生物学功能以及在恶性肿瘤发生发展进程中所起调控作用的研究进展予以综述,希望能为今后判断肿瘤的转归、预后以及肿瘤分子靶向治疗方面提供新思路。
Interleukin-35 （IL-35） produced by regulatory T cells is a newly discovered inhibitory cytokine. It＇s a heterodimer consisting of IL-2713 chain Epstein-Barr virus-induced gene 3 and IL-12α chain p35. In recent years, many studies have found that T cells, B cells, and tumor cells can secrete IL-35, which has a major inhibitory effect on the immune system. IL-35 plays an important role in tumor immune evasion and promotion of tumor progression and metastasis, and is an important factor which promotes the occurrence and development of tumors. Reducing IL-35 secretion may improve disease control, and it is very important to make a thorough inquiry into the role of IL-35 in regulating the activities of tumor cells. This review summarizes the molecular structure, biological functions, and regulatory roles of IL-35 in the development of malignant tumors. It is hoped that it can provide a novel perspective on the judgment of tumor prognosis and tumor targeted molecular therapy in the future.
作者
尹洁
王懿娜
Jie Yin;Yina Wang(Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2018年第10期529-534,共6页
Chinese Journal of Clinical Oncology
基金
浙江省自然科学基金项目(编号:LY16H160006)资助~~
